Aducanumab

Drug Profile

Aducanumab

Alternative Names: Anti-beta amyloid monoclonal antibody - Biogen Idec; BART; BIIB 037; NI-10

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neurimmune Therapeutics
  • Developer Biogen
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 28 Aug 2017 The Ministry of Health, Labour and Welfare designates SAKIGAKE designation dystem aducanumab for Alzheimer's disease in Japan
  • 28 Aug 2017 Updated efficacy and adverse events data from the Long-term extension part of the phase Ib PRIME trial in Alzheimer's disease released by Biogen
  • 08 Dec 2016 Interim efficacy and adverse events data from a phase Ib trial in Alzheimer's disease released by Biogen
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top